Researchers reported that a PET-derived metabolic tumor volume (MTV) biomarker outperformed traditional risk scoring in predicting progression-free survival for patients with large B-cell lymphoma undergoing CAR T therapy. The work positions MTV as a stronger prognostic input than the International Prognostic Index (IPI) for this setting. The findings matter operationally because CAR T outcomes remain highly heterogeneous, and better patient stratification can influence trial design and real-world treatment selection. As cell therapy expands, imaging biomarkers like MTV may become increasingly valuable for refining risk estimates beyond clinical demographics and baseline lab measures.